841 related articles for article (PubMed ID: 21323394)
1. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
[TBL] [Abstract][Full Text] [Related]
2. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
3. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
[TBL] [Abstract][Full Text] [Related]
4. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.
DeMartinis NA; Yeung PP; Entsuah R; Manley AL
J Clin Psychiatry; 2007 May; 68(5):677-88. PubMed ID: 17503976
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
Liebowitz MR; Yeung PP; Entsuah R
J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
[TBL] [Abstract][Full Text] [Related]
7. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder.
Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan P; Kane CP; Cohen LS
Menopause; 2010 Jul; 17(4):700-11. PubMed ID: 20539246
[TBL] [Abstract][Full Text] [Related]
8. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Kornstein SG; Clayton A; Bao W; Guico-Pabia CJ
Menopause; 2014 Aug; 21(8):799-806. PubMed ID: 24448103
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Clayton AH; Kornstein SG; Dunlop BW; Focht K; Musgnung J; Ramey T; Bao W; Ninan PT
J Clin Psychiatry; 2013 Oct; 74(10):1010-7. PubMed ID: 24229754
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder.
Liebowitz MR; Tourian KA; Hwang E; Mele L;
BMC Psychiatry; 2013 Mar; 13():94. PubMed ID: 23517291
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial.
Maity N; Ghosal MK; Gupta A; Sil A; Chakraborty S; Chatterjee S
Indian J Pharmacol; 2014; 46(4):433-7. PubMed ID: 25097285
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
15. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.
Dunlop BW; Reddy S; Yang L; Lubaczewski S; Focht K; Guico-Pabia CJ
J Clin Psychopharmacol; 2011 Oct; 31(5):569-76. PubMed ID: 21869698
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.
Iwata N; Tourian KA; Hwang E; Mele L; Vialet C
J Psychiatr Pract; 2013 Jan; 19(1):5-14. PubMed ID: 23334675
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial.
Rosenthal JZ; Boyer P; Vialet C; Hwang E; Tourian KA
J Clin Psychiatry; 2013 Feb; 74(2):158-66. PubMed ID: 23473348
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.
Liebowitz MR; Manley AL; Padmanabhan SK; Ganguly R; Tummala R; Tourian KA
Curr Med Res Opin; 2008 Jul; 24(7):1877-90. PubMed ID: 18507895
[TBL] [Abstract][Full Text] [Related]
20. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
